Talus Bioscience, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Talus Bioscience, Inc. - overview
Established
2020
Location
Seattle, WA, US
Primary Industry
Biotechnology
About
Based in Washington, US, and founded in 2020 by Alex Federation and Lindsay Pino, Talus Bioscience, Inc. operates as a biotechnology company that is primarily focused on the development of small molecule oncology drugs. Talus Bioscience, Inc. is a pioneer in drug discovery research that has developed a solution that provides complete information on the drug's effectiveness and selectivity in a single test.
The company's platform combines cell manipulation with sensitive quantitative proteomics and advanced machine learning-based analysis. Furthermore, they are working on two projects at the same time to show the potential of their technology in improving gene regulation exploration for drug discovery. Additionally, the firm provides its healthcare sector clients with a valuable tool for advancing gene control drug development.
Current Investors
NFX, The National Institutes of Health, Andy Hill Cancer Research Endowment (CARE) Fund
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Bioinformatics, Therapeutic Devices
Website
www.talus.bio
Verticals
HealthTech
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only
Talus Bioscience, Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.